ABOUT ANSHI
Developing innovative small molecule drugs to revolutionize the treatment of chronic diseases in China.
At A&Z Pharmaceutical (China), our mission is to lead the way in developing cutting-edge compounds to address some of the most pressing healthcare challenges of our time—non-alcoholic steatohepatitis (NASH), obesity, and osteoporosis. We recognize that these conditions affect millions of lives worldwide, and we are driven by a steadfast commitment to bring transformative solutions to patients in need.
We envision a future where NASH, obesity, and osteoporosis are no longer insurmountable health concerns. Instead, they are met with innovative treatments that offer renewed hope, improved well-being, and a better quality of life for patients. Our unwavering dedication to scientific excellence and patient-centric values fuels our quest to redefine healthcare standards and make a tangible impact on global health.
With more than 1,200 employees with diverse technical, business, language and geographical backgrounds and a strong track record of successfully commercializing major drugs in the US & China market, our team understands the regulatory and marketing requirements for success.
External collaboration is woven into the fabric of who we are. Led by Pedram Alaedini, Chief Business Officer, our Business Development team can fully support our strategic intent of any partnership. At Anshi, it is not only about what we achieve, but how we get there. As we seek partnerships, we strive to be all about flexibility and to focus on strategic alliances that can benefit both parties and ultimately being innovative science to patients.
A&Z and Anshi incorporated in the US and China to supply global markets
China manufacturing facility successfully inspected by the US FDA
Biopharmaceutical incorporated
Research & Development Center of Excellence established
Product portfolio expanded by the launch of several major products in China, including ursodeoxycholic acid, the first generic approval in China; Strategic investment in Rabome Inc., FIC drug for osteonecrosis
Synthetic bear bile acid phase Il clinical trials completed
Anshi brings world-class experience at multinational pharmaceutical companies that ensures success for the company’s visionary approach to drug development and commercialization. With a strong track record of successfully introducing major drugs into US and China markets, our team understands the regulatory and market requirements.

Chief Executive Officer

Chief Regulatory & Clinical Officer

Chief Science Officer
Anshi brings world-class experience at multinational pharmaceutical companies that ensures success for the company’s visionary approach to drug development and commercialization. With a strong track record of successfully introducing major drugs into US and China markets, our team understands the regulatory and market requirements.
Meet Our TeamWe are developing treatments for chronic diseases with large unmet clinical need. This includes non-alcoholic steatohepatitis (NASH), obesity and osteoporosis.
Explore Our PipelineAt Anshi, we are committed to pioneering breakthroughs in NASH therapeutics.
Anshi is committed to developing novel pharmaceuticals that address the underlying causes of obesity.
We are dedicated to advancing the field of bone health by developing treatments that not only strengthen bones but also improve overall bone health.